Experts from the Mayo Clinic, widely ranked as the world's top hospital, visited South Korea to explore partnerships with domestic bio-health innovators.
The Korea Trade-Investment Promotion Agency (KOTRA) said on the 27th that it held the Mayo Clinic-DMC Partnership Day over two days starting on the 26th, jointly with the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, the Korea Medical Devices Industry Association and the Korea Healthcare Industry Association.
More than 120 Korean companies in medical artificial intelligence, digital health and home technology took part in the event to discuss global clinical trials and partnership opportunities.
The Mayo Clinic is a comprehensive medical institution that treats more than 1.3 million patients a year from about 100 countries, and it has been named the world's top hospital for eight consecutive years in rankings by the U.S. news magazine Newsweek. The visit included officials from the Mayo Clinic's unit for identifying and supporting innovative companies, as well as from Destination Medical Center (DMC).
On the first day, the Mayo Clinic and DMC introduced their main support programs and joint projects. On the second day, 35 Korean innovative companies held one-on-one meetings with officials from the Mayo Clinic and DMC. Building on actual cases of cooperation that emerged from last year's inaugural event — including clinical validation in the United States and the design of technology verification for Korean companies — participating firms this year presented their technologies and target applications and discussed specific forms of cooperation such as clinical application and validation, joint research and entry into the U.S. market.
KOTRA President Kang Kyung-sung said the expansion of cooperation with one of the world's leading hospitals shows that the technological capabilities of Korean bio-health companies are being proven in the global market. "We will expand opportunities for cooperation with global medical institutions such as the Mayo Clinic so that the medical industry, which will contribute to qualitative growth and diversification in national exports, can establish itself as a new growth engine," he said.
